BRPI1013901A2 - formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos - Google Patents

formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI1013901A2
BRPI1013901A2 BRPI1013901A BRPI1013901A BRPI1013901A2 BR PI1013901 A2 BRPI1013901 A2 BR PI1013901A2 BR PI1013901 A BRPI1013901 A BR PI1013901A BR PI1013901 A BRPI1013901 A BR PI1013901A BR PI1013901 A2 BRPI1013901 A2 BR PI1013901A2
Authority
BR
Brazil
Prior art keywords
neuroprotection
treatment
neurodegenerative disorders
clavulanate
formulation
Prior art date
Application number
BRPI1013901A
Other languages
English (en)
Portuguese (pt)
Inventor
Ho Ahn Chang
Joong Kim Deog
Carl Scholtz Edward
Bok Lee Young
Huh Youngbuhm
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of BRPI1013901A2 publication Critical patent/BRPI1013901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI1013901A 2009-04-29 2010-04-29 formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos BRPI1013901A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17384109P 2009-04-29 2009-04-29
PCT/US2010/032983 WO2010127125A1 (en) 2009-04-29 2010-04-29 Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI1013901A2 true BRPI1013901A2 (pt) 2019-09-24

Family

ID=42261971

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013901A BRPI1013901A2 (pt) 2009-04-29 2010-04-29 formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos

Country Status (11)

Country Link
US (1) US20100255099A1 (enExample)
EP (1) EP2424498A1 (enExample)
JP (1) JP2012525427A (enExample)
KR (1) KR20120012823A (enExample)
CN (1) CN102413814A (enExample)
AU (1) AU2010242948A1 (enExample)
BR (1) BRPI1013901A2 (enExample)
CA (1) CA2758029A1 (enExample)
IL (1) IL215940A0 (enExample)
MX (1) MX2011011459A (enExample)
WO (1) WO2010127125A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0013366A (pt) * 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
MX2010004556A (es) * 2007-10-26 2010-07-01 Rexahn Pharmaceuticals Inc Formulacion farmaceutica de acido clavulanico.
WO2013006808A2 (en) * 2011-07-06 2013-01-10 Rexahn Pharmaceuticals, Inc. Clavulanic acid for treatment of restless legs syndrome
US8978166B2 (en) * 2012-08-27 2015-03-17 Well & David Corp. Multi-function garment
KR102541110B1 (ko) 2014-08-25 2023-06-08 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법
AU2016278846B2 (en) * 2015-06-19 2021-08-05 Biotie Therapies, Inc. Controlled-release tozadenant formulations
WO2020212418A1 (en) * 2019-04-15 2020-10-22 Nanologica Ab Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia.
TWI739220B (zh) * 2019-11-26 2021-09-11 亞瑟瑞智科技管理顧問股份有限公司 包含克拉維酸與丙戊酸之組合物及其用途
CN112843034B (zh) * 2019-11-26 2022-08-23 亚瑟瑞智科技管理顾问股份有限公司 包含克拉维酸与丙戊酸的组合物及其用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110165A (en) * 1974-04-20 1978-08-29 Beecham Group Limited Process for the production of clavulanic acid
CA1085392A (en) * 1976-03-25 1980-09-09 Masayuki Narisada Arylmalonamido-1-oxadethiacephalosporins
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4234579A (en) * 1977-06-07 1980-11-18 Pfizer Inc. Penicillanic acid 1,1-dioxides as β-lactamase inhibitors
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
US4268503A (en) * 1978-09-14 1981-05-19 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
DE3001961C2 (de) * 1980-01-21 1984-08-16 Didier Engineering Gmbh, 4300 Essen Anströmboden für einen Wirbelschichtreaktor
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
US4594247A (en) * 1981-12-21 1986-06-10 Eli Lilly And Company Synergistic antibacterial compositions and method of treatment of infections caused by multiple antibiotic-resistant organisms
JPS59104389A (ja) * 1982-12-06 1984-06-16 Shionogi & Co Ltd オキサセファム誘導体
JPS62106015A (ja) * 1985-10-31 1987-05-16 Sumitomo Pharmaceut Co Ltd 抗痴呆薬
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
GB9201639D0 (en) * 1992-01-25 1992-03-11 Smithkline Beecham Plc Pharmaceutical formulations
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
JP3233407B2 (ja) * 1993-11-06 2001-11-26 大鵬薬品工業株式会社 結晶性ペニシリン誘導体並びにその製造及び使用
US5827537A (en) * 1995-05-04 1998-10-27 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
GB9515411D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9525697D0 (en) * 1995-12-15 1996-02-14 Pharmacia Spa Cephem derivatives
ES2248840T3 (es) * 1996-02-23 2006-03-16 Eli Lilly And Company Antagonistas de vasopresina v1a no peptidilicos.
US5905076A (en) * 1996-04-10 1999-05-18 National Research Council Of Canada 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors
US5795877A (en) * 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US5977090A (en) * 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5863536A (en) * 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6017903A (en) * 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP2002504122A (ja) * 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー ベータラクタマーゼ阻害剤及びその使用方法
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6177421B1 (en) * 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
WO2000045793A1 (en) * 1999-02-04 2000-08-10 Abbott Laboratories Ph independent extended release pharmaceutical formulation
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US6472406B1 (en) * 1999-07-06 2002-10-29 Methylgene, Inc. Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
BR0013366A (pt) * 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
NZ519467A (en) * 1999-12-22 2004-02-27 Pharmacia Corp Dual-release compositions of a cyclooxygenase-2- inhibitor
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
ATE286057T1 (de) * 2000-10-20 2005-01-15 Sandoz Ag Pharmazeutische zubereitungen enthaltend clavulansäure
US7166626B2 (en) * 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
PL371407A1 (en) * 2002-01-10 2005-06-13 Biovail Laboratories Inc. Sedative non-benzodiazepine formulations
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
US7833998B2 (en) * 2003-08-25 2010-11-16 Revaax Pharmaceuticals, Llc Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions
PE20060489A1 (es) * 2004-08-13 2006-06-19 Schering Plough Ltd Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
SI21912A (sl) * 2004-12-24 2006-06-30 Lek Farmacevtska Druzba D.D. Stabilne farmacevtske oblike, ki vsebujejo amoksicilin in klavulansko kislino
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
CA2644911A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
MX2010004556A (es) * 2007-10-26 2010-07-01 Rexahn Pharmaceuticals Inc Formulacion farmaceutica de acido clavulanico.

Also Published As

Publication number Publication date
AU2010242948A1 (en) 2011-11-24
IL215940A0 (en) 2012-01-31
MX2011011459A (es) 2011-11-18
EP2424498A1 (en) 2012-03-07
CA2758029A1 (en) 2011-11-04
US20100255099A1 (en) 2010-10-07
WO2010127125A1 (en) 2010-11-04
CN102413814A (zh) 2012-04-11
JP2012525427A (ja) 2012-10-22
KR20120012823A (ko) 2012-02-10

Similar Documents

Publication Publication Date Title
BRPI1013901A2 (pt) formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
PL2512470T3 (pl) Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
EP2552433A4 (en) COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
PT2470191E (pt) Métodos e composições para prevenção ou tratamento de doenças oftálmicas
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
BRPI0813516A2 (pt) Tratamento de distúrbios proliferativos de células b
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
PL2437742T3 (pl) Nowe kompozycje do leczenia cmt i pokrewnych zaburzeń
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
PT2632300T (pt) Almofada cervical para o tratamento de doenças da coluna cervical
HUE040085T2 (hu) PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
PT2632475T (pt) Composições para o tratamento de úlceras periféricas de várias origens
BRPI0812034A2 (pt) Combinações de neramexano para o tratamento de distúrbios neurodegenerativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.